Table 1: Characteristics of patients who were given a diagnosis with hepatocellular carcinoma (HCC) in Ontario, by sex and year of diagnosis
CharacteristicNo. (%) of patients with HCC
1990−19941995−19992000−2004 2005−2009 Total
Femalen = 177n = 229n = 352n = 475n = 1233
Age at diagnosis, yr
< 6062 (35.0)56 (24.4)77 (21.9)125 (26.3)320 (25.9)
   60−6957 (32.2)73 (31.9)102 (29.0)113 (23.8)345 (28.0)
   70−7938 (21.5)79 (34.5)132 (37.5)150 (31.6)399 (32.4)
> 8020 (11.3)21 (9.2)41 (11.6)87 (18.3)169 (13.7)
Charlson−Deyo comorbidity index
   055 (31.1)101 (44.1)135 (38.3)162 (34.1)453 (36.7)
   121 (11.9)31 (13.5)71 (20.2)89 (18.7)212 (17.2)
   217 (9.6)37 (16.2)40 (11.4)73 (15.4)167 (13.5)
> 36 (3.4)22 (9.6)35 (9.9)42 (8.8)105 (8.5)
No hospitalization record (missing)78 (44.1)38 (16.6)71 (20.2)109 (22.9)296 (24.0)
HCC treatment
Curative29 (16.4)59 (25.8)105 (29.8)179 (37.7)372 (30.2)
Noncurative24 (13.6)32 (14.0)54 (15.3)96 (20.2)206 (16.7)
Palliative care17 (9.6)80 (34.9)160 (45.4)220 (46.3)477 (38.7)
No treatment120 (67.8)105 (45.8)119 (33.8)116 (24.4)460 (37.3)
Malen = 541n = 820n = 1229n = 1822n = 4412
Age at diagnosis, yr
< 60167 (30.9)262 (31.9)468 (38.1)683 (37.5)1580 (35.8)
   60−69213 (39.4)266 (32.4)349 (28.4)479 (26.3)1307 (29.6)
   70−79133 (24.6)244 (29.8)334 (27.2)485 (26.6)1196 (27.1)
> 8028 (5.2)48 (5.8)78 (6.3)175 (9.6)329 (7.5)
Charlson−Deyo comorbidity index
   0169 (31.2)330 (40.2)432 (35.1)540 (29.6)1471 (33.3)
   1104 (19.2)187 (22.8)234 (19.0)379 (20.8)904 (20.5)
   245 (8.3)94 (11.5)156 (12.7)238 (13.1)533 (12.1)
> 319 (3.5)77 (9.4)143 (11.6)222 (12.2)461 (10.4)
No hospitalization record (missing)204 (37.7)132 (16.1)264 (21.5)443 (24.3)1043 (23.6)
HCC treatment
Curative82 (15.2)193 (23.5)400 (32.5)688 (37.8)1363 (30.9)
Noncurative77 (14.2)98 (11.9)223 (18.1)417 (22.9)815 (18.5)
Palliative care72 (13.3)233 (28.4)542 (44.1)841 (46.2)1688 (38.3)
No treatment352 (65.1)412 (50.2)372 (30.3)400 (21.9)1536 (34.8)